Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Mar 22;271(5256):1734-6.
doi: 10.1126/science.271.5256.1734.

Enhancement of Antitumor Immunity by CTLA-4 Blockade


Enhancement of Antitumor Immunity by CTLA-4 Blockade

D R Leach et al. Science. .


One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.

Comment in

Similar articles

See all similar articles

Cited by 858 articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources